chemotherapy. Method: In terms of chemotherapy as the bridge, we performed an indirect comparison of KEYNOTE-189 and IMpower132 to compared therapeutic efficacy and adverse event (AE) between pembrolizumab (N¼410) and atezolizumab (N¼292) in combination with chemotherapy as the first-line treatment of advanced squamous NSCLC. Data of overall survival (OS) and progression-free survival (PFS) were extracted as hazard ratio (HR) and its 95% confidence interval (CI), while data of objective response rate (ORR) and AE were extracted as risk ratio (RR) and its 95% CI. Results: For overall patients, pembrolizumab had significantly superior OS (HR, 0.60, 0.43-0.86; P<0.01) and a significant increase of ORR (RR, 2.09, 1.24-3.52; P<0.01) than atezolizumab in combination with chemotherapy, while they had similar PFS (HR, 0.87, 0.66-1.14; P¼0.31), all cause AE and grade 3-5 AE. For PD-L1 low/high patients, pembrolizumab and atezolizumab showed similar PFS. However, for PD-L1 negative patients, atezolizumab had significantly superior PFS (HR, 1.67, 1.01-2.74; P¼0.04) than pembrolizumab. Conclusion: Our results revealed that anti-PD-1 antibody may have superior efficacy compared to anti-PD-L1 antibody for advanced non-squamous NSCLC patients in combination with chemotherapy as first-line treatment. But anti-PD-L1 antibody might be better for PD-L1 negative patients. Further studies are warranted to confirm this. Keywords: Anti-PD-L1, NSCLC, NonSquamous, Anti-PD-1 in the SEER database. Propensity score matching were performed to balance differences in baseline characteristics between groups. Kaplan-Meier method and Cox proportional hazards model were used to evaluate the impact of prior cancer on overall survival (OS). Results: Among 103,370 eligible lung cancer patients, 15.18% (15696) had a history of prior cancer. Lung (25.83%), breast (14.13%), and prostate (8.85%) were the most common prior cancer. Localized and regional stages were accounting for 61.56% of prior cancers. More than 67.98% of prior cancer were diagnosed within 5 years. The median times of diagnosis for prior cancers were 38 months. The Kaplan-Meier curve (Figure 1 A) show an adverse effect of prior cancer on OS, compared to patients without an prior cancer (p¼0.029). In COX regression analysis, patients with prior cancer had the similar OS as that of patients without a prior cancer (hazard ratio ¼ 1.01, 95% confidence interval¼ 0.99 to 1.04, p¼0.324). Subgroup analyses stratified by timing of prior cancer displayed almost the same tendency (p>0.05) (Figure 1 B) . Early stage patients with prior cancer had adverse survival curves (p<0.05). Advanced stage patients with prior cancer had non-inferior survival (p>0.05). Conclusion: Prior cancer does not convey an adverse effect on clinical outcomes among advanced lung cancer patients age 65 years, regardless of timing of prior cancer. Broader inclusion trial criteria could be adopted in younger advanced lung cancer patients with a history of prior cancer.
Background: Patients with a history of prior cancer are frequently excluded from cancer trials. Previous studies indicated that prior cancer does not adversely impact clinical outcomes for lung cancer patients older than 65 years. However, whether these research results are applicable to lung cancer patients aged younger than 65 years old remains unknown. Method: We identified younger lung cancer patients (<65 years) diagnosed between 2004 and 2009 in the SEER database. Propensity score matching were performed to balance differences in baseline characteristics between groups. Kaplan-Meier method and Cox proportional hazards model were used to evaluate the impact of prior cancer on overall survival (OS). Results: Among 103,370 eligible lung cancer patients, 15.18% (15696) had a history of prior cancer. Lung (25.83%), breast (14.13%), and prostate (8.85%) were the most common prior cancer. Localized and regional stages were accounting for 61.56% of prior cancers. More than 67.98% of prior cancer were diagnosed within 5 years. The median times of diagnosis for prior cancers were 38 months. The Kaplan-Meier curve (Figure 1 A) show an adverse effect of prior cancer on OS, compared to patients without an prior cancer (p¼0.029). In COX regression analysis, patients with prior cancer had the similar OS as that of patients without a prior cancer (hazard ratio ¼ 1.01, 95% confidence interval¼ 0.99 to 1.04, p¼0.324). Subgroup analyses stratified by timing of prior cancer displayed almost the same tendency (p>0.05) (Figure 1 B) . Early stage patients with prior cancer had adverse survival curves (p<0.05). Advanced stage patients with prior cancer had non-inferior survival (p>0.05). Conclusion: Prior cancer does not convey an adverse effect on clinical outcomes among advanced lung cancer patients age 65 years, regardless of timing of prior cancer. Broader inclusion trial criteria could be adopted in younger advanced lung cancer patients with a history of prior cancer. Keywords: SEER, Survival, Prior cancer, lung cancer 
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